Harvard Breast Cancer: New Horizons, Current Controversies 2025 (Videos + Slides)

Overview

Harvard Breast Cancer: New Horizons, Current Controversies 2025 (Videos + Slides) is a comprehensive on-demand course designed to enhance clinical expertise in breast oncology by presenting the latest advances in diagnosis, treatment, and survivorship care. This program covers a broad spectrum of breast cancer management, including disease mechanisms, diagnostic improvements, therapeutic innovations, and survivor support, providing valuable insights for oncology specialists across disciplines.

On-demand oncology education — accessible anytime, anywhere.

Format: Videos and slides

Agenda

This course delivers extensive content through recorded sessions from the 2025 two-day program, featuring expert-led presentations, panel discussions, and case reviews across all breast cancer subtypes and treatment modalities.

• Welcoming Remarks — Harold Burstein
• 50 Years of Radiation Therapy — Abram Recht
• Standard Radiation Therapy: The Long and the Short — Julia Wong
• The Future of Breast Radiation Therapy — Atif Khan
• Radiopharmaceuticals — Heather Jacene
• Q&A — Abram Recht, Atif Khan, Julia Wong, Heather Jacene
• Lobular Breast Cancer — Stuart Schnitt
• ctDNA: The Evolving Role for Molecular Diagnostics — Stefania Morganti
• Q&A — Stuart Schnitt, Stefania Morganti
• Essentials of Germline Genetics — Judy Garber
• Q&A — Julie Bosworth, Sydney Smith, Judy Garber
• What’s New in Supportive Care: Management of Gastrointestinal Side Effects — Sydney Smith, Julie Bosworth
• Schwartz Rounds: A Complex Case — Ann Partridge
• Tumor Board: Early Breast Cancer — Harold Burstein, Faina Nakhlis, Julia Wong, Brittany Bychkovsky, Adrienne Waks, Filipa Lynce, Elizabeth Mittendorf
• New Approaches in Early Stage HER2 Positive Breast Cancer — Adrienne Waks
• The Progress Continues: Late Stage HER2 Positive Breast Cancer — Sarah Sammons
• Can We Cure Metastatic Breast Cancer? — Nancy Lin
• Q&A — Sara Tolaney, Sarah Sammons, Nancy Lin, Adrienne Waks
• Racial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype — Erica Warner
• Inflammatory Breast Cancer — Filipa Lynce
• Early Drug Discovery in Breast Cancer — Antonio Giordano
• Lifestyle/Diet/Exercise in Breast Cancer Patients — Jennifer Ligibel
• Oncoplastic Reconstruction: Common Indications and Outcomes — Indranil Sinha
• The Axilla After Neoadjuvant Therapy: How Much Is Too Much? — Elizabeth Mittendorf
• Implications of the SOUND Trial — Olga Kantor
• Cryoblation Instead of Surgery — Francys Verdial
• Q&A — Barbara Smith, Indranil Sinha, Olga Kantor, Francys Verdial, Elizabeth Mittendorf
• Immunotherapy in Early Breast Cancer: Today and Tomorrow — Marleen Kok
• Small TNBCs: How Small Is Small Enough? — Steven Isakoff
• Antibody Drug Conjugates in TNBC and Refractory ER Positive Metastatic Breast Cancer — Ana Garrido-Castro
• Immunotherapy in TNBC — Guilherme Nader Marta
• Managing Endocrine Side Effects of Immunotherapy — Elad Sharon
• Q&A — Steven Isakoff, Ana Garrido-Castro, Guilherme Nader Marta, Elad Sharon
• Tumor Board: Advanced Breast Cancer — Rachel Freedman, Barbara Smith, Sarah Sammons, Erica Mayer, Laura Spring, Leticia Varella, Guilherme Nader Marta, Daniel Abravanel
• New Approaches in Early ER Positive Breast Cancer — Erica Mayer
• PI3K Inhibitors in Metastatic Breast Cancer: Choosing the Right Target — Dejan Juric
• Advanced ER Positive Breast Cancer: A Surfeit of Choices — Seth Wander
• Emerging Antibody Drug Conjugates in ER Positive Breast Cancer — Paolo Tarantino
• Q&A — Erica Mayer, Seth Wander, Paolo Tarantino, Dejan Juric
• CDK4/6: Which One? For Whom? – Debate — Shana Berwick, Laura Spring
• ASCO Highlights — Harold Burstein
• Closing Remarks — Harold Burstein

Learning Objectives

• Apply knowledge of recent clinical data with current expert recommendations to select appropriate therapies for advanced breast cancer.
• Utilize risk assessment tools and evidence-based strategies for patients undergoing neoadjuvant or adjuvant therapy, understanding limitations of genomic testing.
• Manage post-mastectomy patients effectively by integrating surgical treatments, reconstruction options, and radiation therapy as appropriate.
• Improve symptom management during treatment and survivorship, including fertility and lifestyle counseling for patients and survivors.
• Assess genetic and personal risk factors and implement appropriate genetic testing for hereditary breast cancer.

Speakers

This course features clinical experts in medical, surgical, and radiation oncology, as well as pathology and genetics. Faculty members contribute the latest evidence-based knowledge and clinical experience to support learning in breast cancer care.

• Harold Burstein, MD, PhD
• Abram Recht, MD
• Julia Wong, MD
• Atif Khan, MD
• Heather Jacene, MD
• Stuart Schnitt, MD
• Stefania Morganti, MD
• Judy Garber, MD, MPH
• Julie Bosworth, MD
• Sydney Smith, MD
• Ann Partridge, MD
• Faina Nakhlis, MD
• Brittany Bychkovsky, MD
• Adrienne Waks, MD
• Filipa Lynce, MD
• Elizabeth Mittendorf, MD
• Sarah Sammons, MD
• Nancy Lin, MD
• Sara Tolaney, MD
• Erica Warner, PhD
• Antonio Giordano, MD, PhD
• Jennifer Ligibel, MD
• Indranil Sinha, MD
• Olga Kantor, MD
• Francys Verdial, MD
• Barbara Smith, MD
• Marleen Kok, MD
• Steven Isakoff, MD, PhD
• Ana Garrido-Castro, MD
• Guilherme Nader Marta, MD
• Elad Sharon, MD
• Rachel Freedman, MD
• Erica Mayer, MD
• Laura Spring, MD
• Leticia Varella, MD
• Daniel Abravanel, MD
• Dejan Juric, MD
• Seth Wander, MD
• Paolo Tarantino, MD
• Shana Berwick, MD

Target Audience

This course is intended for medical, surgical, and radiation oncologists, breast and general surgeons, internists, physician assistants, nurse practitioners, oncology nurses, and other healthcare professionals involved in breast cancer patient care seeking to update their knowledge with recent advances and practical clinical applications.

Why This Topic Matters

Harvard Breast Cancer: New Horizons, Current Controversies 2025 (Videos + Slides) addresses critical advances and ongoing debates in breast oncology, encompassing diagnostics, surgical approaches, systemic treatments, and survivorship care. It supports oncology professionals in maintaining current, evidence-based proficiency in this rapidly evolving specialty.

Presented via MedHub Central, this course provides a reliable platform for comprehensive breast cancer education, bridging the gap between emerging research and clinical practice to strengthen expertise and support informed decision-making in patient management.